In this study we cross-reference several nationwide high-quality Swedish registers in order to study risk factors for severe Covid-19 outcomes.
In this nationwide, case-control study we cross-reference several detailed, high-quality Swedish registers in order to study risk factors associated with severe Covid-19 as well as different disease outcomes, with a focus on cardiovascular disease, chronic kidney disease, different treatments and socioeconomic factors. Cases are identified through the Swedish intensive care register (SIR) and controls through the Swedish population register (RTB). Further information on the study participants is gathered by linkage to registers on: prescribed drugs; history of in- and outpatient care; income, education and migration. Follow-up data such as future hospitalization and mortality will be gathered prospectively.
Study Type
OBSERVATIONAL
Enrollment
22,784
Exposure : Any registered diagnosis of I10 within 15 years or a registered pick-up of a prescription of antihypertensive treatment (ATC C02CA, C02DB02, C03, C07, C08, C09) within one year before index date in the Swedish prescribed drug register (exluding those with a registered diagnosis of other indications for betablocker (heart failure, atrial fibrillation) or ACE-inhibitor, ARB(heart failure) ) Exposures will be compared between cases and controls and between cases with different outcomes and controls
Exposure: Any registered diagnosis of E11 within 15 years or a registered pick-up of a prescription with any antidiabetic treatment (ATC A10) within one year before index date in the Swedish prescribed drug register. Exposures will be compared between cases and controls and between cases with different outcomes and controls
Södersjukhuset
Stockholm, Sweden
Severe Covid-19
Admitted to ICU in Sweden with a main diagnosis of Covid-19 confirmed by laboratory testing (ICD 10: U07.1) and requring mechanical ventilation
Time frame: 2020-03-01 to 2020-05-11
Severe Covid-19 with pulmonary embolism
Admitted to ICU in Sweden with a diagnosis of Covid-19 confirmed by laboratory testing (ICD 10: U07.1) and a bidiagnosis of pulmonary embolism (ICD10:I26)
Time frame: 2020-03-01 to 2020-05-11
CRRT(Continuous Renal Replacement Therapy)
Number of participants admitted to ICU in Sweden with a verified diagnosis of Covid-19 requring CRRT
Time frame: 2020-03-01 to 2020-05-11
ECMO (Extracorporeal Membrane Oxygenation )
Number of participants admitted to ICU in Sweden with a verified diagnosis of Covid-19 requring ECMO
Time frame: 2020-03-01 to 2020-05-11
ICU Mortality
Number of participants admitted to ICU in Sweden with a verified diagnosis of Covid-19 with death occurring in ICU after admission
Time frame: 2020-03-01 to 2020-05-11
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Exposure: Diagnosis ICD E66 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes and controls
Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date. Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls
Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
Exposure: Diagnosis ICD N18 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes (mechanical ventilation, continuous renal replacement therapy mortality) and controls. Exposures will thereafter be compared in subgroups by BMI at ICU-admission and in subgroups matched by history of type 2 diabetes.